Study of Lusutrombopag and Recombinant Human Thrombopoietin to Treat Low Platelet Counts in Adults with Chronic Liver Disease Undergoing Planned Invasive Surgery

What this Trial Is About

Researchers are evaluating the effects of lusutrombopag combined with recombinant human thrombopoietin in treating thrombocytopenia in patients with chronic liver disease who are scheduled for elective invasive surgery. This Phase 2 study aims to assess both the safety and efficacy of this combined treatment approach in improving platelet counts before surgery. Participants will receive the combined treatment starting on the first day after eligibility is confirmed, continuing daily for seven days. The study focuses on patients undergoing planned surgeries expected to occur between days 9 and 15 after enrollment, excluding extremely high-risk surgeries such as open abdomen, chest, skull, or cardiac surgeries. During the study, participants will be monitored to measure the percentage of responders by day 8 and the proportion achieving sufficient platelet counts before surgery. Researchers will also track bleeding emergencies and the use of platelet transfusions during procedures. The total study duration includes treatment and observation around the surgical period, with safety and efficacy evaluated through routine blood tests and clinical assessments.

Lusutrombopag Combined With Recombinant Human Thrombopoietin for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Destined to Undergo Elective Invasive Surgery